Cancers Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

Ghaneya Al-Khadairi 1 and Julie Decock 1,2,*

1 College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, Qatar
2 Cancer Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, Qatar
* Correspondence: juliedecock80@gmail.com or jdecock@hbku.edu.qa

Received: 11 June 2019; Accepted: 10 July 2019; Published: 15 July 2019

Abstract: PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.

Keywords: PRAME; cancer testis antigen; cancer vaccine; adoptive T cell therapy; immunotherapy; antibody

1. Introduction

Conventional cancer care, including surgery, radiotherapy, and chemotherapy, considerably prolongs the survival of patients; however, a significant proportion of cancer patients do not respond to standard systemic therapy or relapse after treatment. The need for alternative, well-tolerated first-line treatments has been partially met by the development of targeted therapies involving a number of novel therapeutic drugs that target specific molecules. For example, antibody-based targeting of the Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (Her2), and Cluster of Differentiation 20 (CD20) are currently used as standard targeted treatments in lymphoma, breast, colorectal, and head and neck cancers [1–3]. Despite initial success with targeted therapy, many patients develop resistance and do not benefit from the treatment in the long term. Thus, the need for alternative, well-tolerated cancer treatment strategies that can induce durable clinical responses remains. Recently, cancer immunotherapy has been acclaimed as the long-awaited breakthrough in cancer treatment, providing durable and potent clinical efficacy in a range of cancer types. The revolutionary nature of immunotherapy is evident from the success stories using immune checkpoint inhibitors. Checkpoint blockade using antibodies against Programmed Death 1 (PD-1) or its ligand, Programmed Death Ligand 1 (PD-L1), and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4) has greatly enhanced the anti-tumor immune response, improving clinical outcomes and leading to durable responses in numerous cancers [4]. Furthermore, cellular immunotherapy using ex vivo expanded circulating antigen-specific T cells or tumor infiltrating lymphocytes (TILs) and engineered T cells has gained interest in the field, as it does not rely on the patient to actively generate large numbers of antigen-specific immune cells and has shown a significant increase in durable complete response rates across malignancies [5]. Treatment with autologous expanded TILs has resulted in durable complete responses in 22% of metastatic melanoma patients at up to 109 months.
Likewise, durable responses have been obtained using autologous T lymphocytes that are engineered to target intracellular antigens through T cell receptors (TCRs) or cell surface antigens through Chimeric Antigen Receptors (CARs), followed by ex vivo expansion into sufficient numbers and selection for avidity and activity prior to infusion into the patient. The success of engineered T cell therapy is apparent from clinical trials with CD19-CAR T cells, where 61–93% of patients with B cell acute lymphoblastic leukemia achieved a complete response at up to 18 months, and from the trials with NY-ESO-1 specific TCR T cells where objective responses were observed in 55% of melanoma patients with a 5 year survival rate of 33% [7–9]. However, the clinical utility of adoptive T cell therapy is challenged by the identification of candidate target antigens with limited on-target and/or off target toxicity. In this respect, cancer testis antigens (CTAs) have been considered promising targets for adoptive T cell therapy thanks to their restricted expression in somatic normal tissues, re-expression in many cancer types, and immunogenic nature [10]. Approximately half of all CTAs are encoded on the X-chromosome, aptly termed CT-X antigens. Together they make up 10% of all genes on the chromosome and are induced by demethylation during spermatogenesis [11].

CTA re-expression in tumors has been linked with worse clinical outcome in various cancers [12]. Since the majority of CTAs are intracellular proteins, efforts to develop CTA-based cellular immunotherapy have focused on the isolation and expansion of circulating CTA-specific T cells and on the engineering of antigen-specific TCR T cells. Among all candidate CTAs, MAGE-A3, NY-ESO-1, and PRAME have shown great potential as prognostic biomarkers and immunotherapeutic targets [9,13]. This review focuses on PRAME, which presents an attractive approach for CTA-based immunotherapy, as it displays few unique features in comparison to other cancer testis antigens, which are highlighted in this review.

2. PRAME Expression in Healthy and Neoplastic Tissues

PRAME, also known as CT130, MAPE (Melanoma Antigen Preferentially Expressed in tumors) or OIP4 (OPA-Interacting Protein 4), is encoded over a region of approximately 12 kilobases on chromosome 22 at locus 22q11.22. It was first identified as a tumor antigen that could be recognized by human leukocyte antigen (HLA)-A*24 restricted cytotoxic T lymphocytes in metastatic cutaneous melanoma [14]. PRAME is better classified as a testis-selective rather than a testis-restricted CTA, as low RNA expression has been observed in endometrial, ovarian, and adrenal gland tissues in addition to the testes [15]. PRAME expression is primarily upregulated by DNA demethylation, at least in part in conjunction with binding of the transcription factor MZF1, with recent evidence suggesting that aberrant PRAME expression can also be induced by miRNA-211 downregulation [16,17]. PRAME is re-expressed in a wide range of cancers, including melanoma [18,19], renal cell cancer [20], non-small cell lung cancer (NSCLC) [21], neuroblastoma [22], breast cancer [23,24], multiple myeloma [25,26], acute leukemia [27,28], chronic myeloid leukemia [25,29], multiple sarcoma subtypes [30,31], and primary and metastatic uveal melanoma [32,33]. Given the widespread expression of PRAME across different cancers, it is important to consider its heterogeneity of expression, as this may limit the PRAME-specific therapeutic response. Cancer testis antigens such as the well-studied NY-ESO-1 are expressed at different levels within a single tumor; hence, it is not unlikely that PRAME expression might also display intra-tumor heterogeneity [34,35]. In accordance, differences in PRAME expression were found among 14 single cell clones derived from a single cutaneous melanoma lesion, suggesting that the presence of low expressing cell clones may allow cancer cells to escape PRAME-targeted immunotherapy [34]. One approach to overcome treatment resistance by these distinct clones would be to induce PRAME expression for targeting purposes. Indeed, several studies have demonstrated that treatment with the demethylating agent 5′-aza-2′-deoxycytidine can successfully induce the expression of CTAs, including PRAME [36–38]. Moreover, PRAME expression has been associated with poor prognosis in solid cancers including breast cancer [23,24], sarcoma [39–41], head and neck cancer [42], medulloblastoma [43], uveal melanoma [32,33], and neuroblastoma [22].
In contrast, a number of reports have suggested that increased PRAME expression is associated with a favorable outcome and treatment response in various hematological malignancies [44–48]. Its prognostic significance is further corroborated by its value for monitoring minimal residual disease in patients with acute leukemia [44,45,49]. Together these findings suggest that PRAME could be a valuable target for immunotherapy alongside its fellow cancer testis antigen NY-ESO-1.

3. Biological Functions of PRAME in Cancer

The cellular and molecular functions of PRAME in normal and neoplastic cells remain largely unclear and may differ depending on tissue-specificity and/or subcellular localization of PRAME. PRAME was identified as a dominant repressor of retinoic acid (RA) signaling, thereby inhibiting differentiation, proliferation arrest, and apoptosis [50]. Its overexpression was found to inhibit myeloid cell differentiation of leukemic progenitor cells [51]. In line with this, leukemic CD34+ progenitor cells of patients with advanced phase CML express high levels of PRAME in comparison to the CD34+ cells of healthy individuals [52]. Of note, the silencing of PRAME could restore sensitivity to retinoic acid treatment in RA-resistant melanoma cell lines, thereby reducing cancer cell proliferation by de-repressing the expression of RAR target genes [50]. However, whether the increased expression of PRAME could be linked to resistance to all-trans retinoic acid (ATRA) therapies in patients with acute promyelocytic leukemia (APL) remains to be determined [53]. In this respect, PRAME targeting could offer a unique opportunity, not bestowed to other CTAs, to enhance the treatment response to ATRA treatment.

In recent years, however, it has become apparent that PRAME could promote tumor development and progression via different mechanisms. Its nuclear localization has been implicated in transcriptional regulation, thereby possibly driving the expression of genes that are involved in tumor promotion. More specifically, analysis of the PRAME interactome revealed that PRAME facilitates the recruitment of Cullin2 ubiquitin ligases to the EKC/KEOPS complex in the nucleus, which is involved in telomere maintenance, transcriptional regulation, and threonylcarbamoyladenosine (t6A) modification of transfer RNAs (tRNA) for accurate decoding of A-starting mRNA codons [54–56].

Furthermore, the increase in PRAME expression with more advanced disease and a higher risk of metastasis suggests that PRAME plays a role in the acquisition of various cancer hallmarks, including replicative immortality or stemness, and invasion and metastasis [32,33,39–41,57,58]. Thus, we recently explored the biological mechanisms by which PRAME could facilitate cancer cell motility as one of the major biological processes involved in regulating metastatic behavior [59]. We demonstrated that PRAME increased the migratory and invasive behavior of triple negative breast cancer cells in vitro by promoting the epithelial-to-mesenchymal transition (EMT).

In addition to supporting tumor cell features, PRAME has been implicated in the regulation of the immune response. Homology sequence analyses revealed that PRAME contains 21.8% (iso)leucine residues, and hence belongs to the leucine-rich repeat (LRR) family of proteins [25]. Furthermore, structural analyses indicated similarities with Toll-like receptors (TLR3 and TLR4) that play an important role in the recognition of pathogen-associated molecular patterns (PAMPs) during antimicrobial immune responses. In a follow-up study, the authors demonstrated that PRAME is upregulated in response to bacterial PAMPs and IFN-γ, followed by translocation to the Golgi network where it co-localizes with the Elongin/Cullin E3 ubiquitin ligase complex [60]. This suggests that cytoplasmic PRAME might be involved in protein ubiquitylation in response to pro-inflammatory stimuli. How PAMP/IFN-γ treatment induces PRAME expression remains unknown, but this could involve the activation and binding of transcription factors to the proximal promoter of PRAME, including nuclear factor kappa B (NFkB), interferon regulatory transcription factors (IRFs), and signal transducers and activators of transcription (STATs) [61]. PRAME has the ability to bind to bacterial OPA proteins, further supporting a role for PRAME in the innate immune response [62]. This raises the question of whether PRAME could be involved in regulating the adaptive anti-tumor immune response, corroborating its value as an immunotherapeutic target in comparison to other CTAs. Moreover, given the association of PRAME
expression with favorable outcomes in hematological diseases, directly targeting PRAME by small molecule inhibitors or gene silencing might not be as beneficial as compared with cytotoxic targeting of the tumor cells expressing PRAME.

4. PRAME-Targeted Immunotherapy

The restricted re-expression of PRAME across malignancies renders it a candidate target for cancer treatment and has sparked numerous studies on the development and evaluation of immune-based interventions targeting PRAME. A variety of immunotherapy strategies are currently developed with the common goal of eliciting durable and potent anti-tumor immune responses. To date, efforts in PRAME immune-based targeting have focused on cancer vaccines and adoptive T cell therapies, as described below. Ongoing clinical trials of cellular immunotherapies targeting PRAME are summarized in Table 1.

| NCT Number   | Other ID | Intervention                                      | Disease                                                                 |
|--------------|----------|--------------------------------------------------|------------------------------------------------------------------------|
| NCT01333046  | H-27471, ACTAL | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, Survivin and SSX), and Azacitidine | Hodgkin lymphoma, non-Hodgkin lymphoma, Hodgkin disease                |
| NCT02203903  | RESOLVE | Multi TAA T cells (WT1, PRAME, and Survivin)     | Relapsed/refractory hematopoietic malignancies (ALL, AML, CML, MDS)     |
| NCT02239861  | H-35425, TACTASOM | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX) | Rhabdomyosarcoma                                                       |
| NCT02291848  | H-35626, TACTAM | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX) | Multiple myeloma                                                        |
| NCT02475707  | H-37042, STELLA | Multi TAA T cells (WT1, PRAME, and Survivin)     | Leukemia, ALL                                                          |
| NCT02494167  | H-36346, ADSPAM | Multi TAA T cells (WT1, NY-ESO-1, PRAME, and Survivin) | AML, MDS                                                               |
| NCT02743611  | BP-011 | BPX-701 and Rimiducid                             | AML, MDS, uveal melanoma                                                |
| NCT02789228  | 7497 | Multi TAA T cells (WT1, PRAME, and/or Survivin) | Solid tumors                                                           |
| NCT03093350  | H-39209, TACTIC | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX2) | Breast cancer                                                          |
| NCT03192462  | H-40378, TACTOPS | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX2) | Pancreatic cancer                                                       |
| NCT03503968  | CD-TCR-001 | MDG1011                                          | High risk myeloid and lymphoid neoplasms                               |
| NCT03652545  | REMIND | Multi TAA T cells (WT1, PRAME, and/or Survivin)  | Brain tumor                                                            |

TAA, tumor associated antigen; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BPX-701, PRAME-TCR T cells with iCasp9; CML, chronic myeloid leukemia; MDG1011, PRAME-TCR T cells; MDS, myelodysplastic syndromes; Rimiducid, homodimerizing tacrolimus analogue.

4.1. Cancer Vaccines

Clinical trials on PRAME cancer vaccines have reported no major toxicities in patients with various solid cancers; however, thus far, the therapeutic benefits have been rather limited, hence discouraging the further development of PRAME vaccines [63,64]. A first hint at a possible explanation for these suboptimal results can be traced back to the lack of CD8+ cytotoxic T cell responses in the early preclinical study of the acellular recPRAME+AS15 vaccine containing the recombinant PRAME protein (recPRAME) and the AS15 immunostimulant (AS15) [65]. Whereas PRAME-specific humoral and CD4+ and CD8+ responses were observed in HLA-A02.01/HLA-DR1 transgenic mice, no CD8+ responses were detected in nonhuman primates (cynomolgus monkeys). These findings were corroborated in
phase I dose escalation studies in human metastatic melanoma (NCT01149343) and non-small cell lung cancer (NCT01159964), demonstrating PRAME-specific antibodies and CD4+, but not CD8+, T cell responses [63,66]. This phenomenon is not restricted to PRAME but has also been observed when targeting other tumor-associated, but not tumor-selective, antigens, and it might be related to the negative selection of high affinity T cell responses in the thymus. Indeed, given the low expression of PRAME in endometrial, ovarian, and adrenal gland tissues, it is likely that high affinity PRAME-reactive cytotoxic T cells undergo negative thymic selection in order to avoid autoimmune responses against those normal tissues where PRAME expression could be regarded as a self-antigen. Further evaluation of this vaccine in a phase II NSCLC study (NCT01853878) was terminated prematurely, as the benefit of CTA cancer vaccines in NSCLC was questioned given the strong immunosuppressive environment of NSCLC tumors and the lack of improvement in clinical outcomes of a phase III randomized MAGE-A3 vaccination study [67]. In contrast, promising results have been obtained using a cancer vaccine targeting PRAME together with prostate-specific membrane antigen (PSMA). Treatment with this multi-tumor associated antigen (TAA) vaccine resulted in the expansion of the antigen-specific CD8+ T cell population with stable disease (6 to 18+ months) in four out of ten patients with refractory prostate cancer and in two out of two patients with metastatic renal clear cell carcinoma [64]. Another multi-TAA peptide vaccine approach directed against PRAME, NY-ESO-1, MAGE-A3, and WT-1 in combination with 5’-aza-2’-deoxycytidine is currently in phase I trial in patients with myelodysplastic syndrome and acute myeloid leukemia (NCT02750995). In comparison to peptide cancer vaccines, cellular vaccine therapy targeting PRAME is a less active and well-developed field. Currently, only one clinical trial is exploring the safety and efficacy of WT1/PRAME-loaded dendritic cells in patients with acute myeloid leukemia in remission (NCT02405338). Potentially, cellular vaccines could confer a greater efficacy through the specific priming of pre-existing antigen-specific T cell clones.

4.2. Adoptive T Cell Therapy

Cellular immunotherapy with PRAME-specific T cells has largely been explored using two different approaches involving either the isolation of pre-existing circulating PRAME-specific T cells for ex vivo expansion and selection, or the genetic engineering of high-affinity PRAME-specific TCR T cells. As aforementioned, PRAME was originally identified through the detection of specific tumor-reactive HLA-A*24–restricted T cell clones in a metastatic melanoma patient [14]. Analysis of proteasome cleavage of PRAME polypeptides in conjunction with in silico epitope prediction identified four additional HLA-A*0201–restricted epitopes: PRA100-108 (VLDGLDVLL), PRA142-151 (SLYSFPEPEA), PRA300-309 (ALYVDSLFFL), and PRA425-433 (SLLQHLIGL) [68]. Following the identification of these candidate epitopes, patients’ blood samples were screened to evaluate each epitope’s ability to induce specific T cells, thereby providing a rationale for cellular immunotherapy using ex vivo expansion of circulating autologous antigen-specific T cells. In vitro priming of isolated peripheral blood mononuclear cells with peptide-pulsed autologous antigen presenting cells demonstrated the presence of PRA100-108 and PRA300-309-specific T cells in 36% of melanoma and 70% of AML cancer patients, respectively [48,69]. Furthermore, the ex vivo expanded PRA100-108 and PRA300-309-specific T cells exhibited cytotoxic activity against autologous chronic myeloid leukemia (CML) blasts and cancer cell lines of various histologic origins [69,70]. However, these T cell clones have a rather low affinity, possibly due to the aforementioned thymic negative selection of high-affinity clones, which limits their clinical application. In order to increase the avidity, polyclonal multivalent cytotoxic lymphocytes were generated from healthy donors and leukemia patients using a peptide library of 125 synthetic pentadecapeptides [70]. Of note, a large proportion of the cells showed activity against a novel HLA-A*02–restricted epitope (NLTHVLYPV, PRA435-443) that is expressed in HLA-A*02+ PRAME+ tumor cell lines and primary leukemic blasts. These high-avidity T cells not only showed activity against leukemic blasts but also against leukemic progenitor cells without affecting normal hematopoietic precursors, thereby expanding the pool of neoplastic cells that can be targeted by PRAME adoptive T cell therapy. In parallel, another research group isolated
PRAME-specific HLA-A2 restricted T-cell clones with high specificity for PRAME (HSS1 and HSS3) as a result of a graft-versus-host immune response to an HLA-A2 mismatched stem cell transplantation [71]. These T cells were able to recognize various PRAME-expressing cell lines derived from melanoma, acute myeloid leukemia, colon carcinoma, cervix carcinoma, and lung and breast cancer, whereas acute lymphoblastic leukemia cells were only recognized after CD40L-activation of the T cell clones. To date, numerous ongoing clinical trials are studying the safety and efficacy of targeting PRAME using ex vivo expanded multi-TAA-specific T cells in hematological malignancies (NCT02291848, NCT02475707, NCT02494167 and NCT02203903), neuro-oncologic disease (NCT03652545), rhabdomyosarcoma (NCT02239861), pancreatic cancer (NCT03192462), breast cancer (NCT03093350), and a range of high-risk solid tumors (NCT02789228).

In comparison to the research efforts on cellular therapy using pre-existing autologous PRAME-specific T cells, there is very limited published information on PRAME genetically modified T cell therapy. Notwithstanding, adoptive therapy using TCR transduced T cells has shown encouraging results in generating durable responses in selected cancer types, resulting in a surge of clinical trials targeting various tumor-associated antigens, including the cancer testis antigens NY-ESO-1. For instance, NY-ESO-1 specific TCR-T cells are currently being evaluated in numerous clinical trials following encouraging results with improved clinical response rates and prolonged survival of patients with metastatic melanoma, synovial sarcoma, and multiple myeloma [9]. A recent study reported that the transduction of T cells with a high affinity PRAME TCR and an inducible caspase-9 safety switch (BPX-701) eliminated the genetically modified T cells in case of detrimental toxicity [43]. The BPX-701 TCR T cells were capable of eradicating both medulloblastoma cell lines and primary medulloblastoma cells in vitro. Moreover, the transduced T cells induced tumor regression in an orthotopic medulloblastoma mouse model without excess neurological toxicity and were successfully eradicated by the suicide gene. These BPX-701 T cells are currently under evaluation in a phase I clinical trial in patients with relapsed AML, refractory myelodysplastic syndrome (MDS), and metastatic uveal melanoma (NCT02743611). A second clinical trial with a different type of PRAME TCR T cells (MDG1011) will evaluate their safety and efficacy in patients with AML, MDS, and multiple myeloma (NCT03503968).

It is important to note that the efficacy of adoptive T cell therapy is not only determined by the avidity of the T cell clones but also by the expression level of the target throughout the tumor. As mentioned earlier, tumors often show heterogeneous tumor-associated antigen expression patterns so that distinct tumor cell clones with absent or relatively low target expression might escape T cell killing. In order to tackle this, it would be beneficial to induce re-expression of the target in all tumor cells using demethylating agents (DNA), histone deacetylase inhibitors (HDACi), or a combination of both. These epigenetic modulators have been successfully used to upregulate tumor PRAME expression, resulting in an increase in cytolytic activity of ex vivo expanded autologous T cells [72,73]. The approach to combine demethylating agents with PRAME T cell transfer is currently under phase I clinical trial using 5′-aza-2′-deoxycytidin and multi-TAA TCR T cells targeting up to five antigens (NY-ESO-1, MAGEA4, PRAME, Survivin and SSX) in Hodgkin and non-Hodgkin lymphoma (NCT01333046).

5. Current Challenges and Opportunities for PRAME-Targeted Immunotherapy

PRAME has emerged as a potential candidate target for immunotherapy, and we are currently awaiting the results from numerous clinical trials evaluating PRAME-specific cancer vaccines and adoptive T cell therapies. Although preclinical studies have been promising, we should be vigilant and anticipate, as for any novel treatment approach, that PRAME-targeted immunotherapy might face challenges in the clinic. As depicted in Figure 1, every challenge can be seen as a novel opportunity for treatment development and improvement. PRAME expression has traditionally been observed in the nucleus and cytoplasm of tumor cells; therefore, immune-based strategies designed towards intracellular targets have been the treatment of choice, including acellular and cellular cancer vaccines and adoptive T cell therapy with autologous or TCR-engineered T cells. Recent evidence suggests that PRAME could be targeted as a membrane-bound protein using a specific monoclonal antibody
(mAb) [74] or TCR mimic antibody (TCRm) [75,76], which also opens up the possibility for CAR-based T cell therapy. Overall, the efficacy of targeted immunotherapy may be hampered due to intra-tumor heterogeneity, loss or downregulation of HLA class I molecules as well as expression of immune checkpoint molecules such as PD-L1. Countermeasures for these include demethylation agents and histone deacetylase inhibitors to increase target expression, and MEK inhibitors and NK cell therapy to induce HLA expression. Immune checkpoint blockade could be used in combination with any of the PRAME-targeting approaches.

**Figure 1.** Immunotherapy approaches to target specific tumor-associated antigens such as PRAME.

As a first challenge, the heterogeneity of PRAME expression could likely present a bottleneck for the efficient targeting and complete eradication of tumor cells. Firstly, PRAME expression shows a wide range of inter-tumor heterogeneity among patients carrying tumors of the same tissue origin, thereby limiting the overall response rate. This is of particular importance for breast cancer where only 27% of tumors display PRAME expression [19]. Secondly, tumor types that are defined as PRAME-positive might display significant intra-tumoral heterogeneity, leading to treatment resistance due to the low expressing cell clones. This dose-dependent immune response has been demonstrated in the context of PRA100-108 specific T cell activation in HLA-A*0201+ acute lymphocytic leukemia (ALL) and melanoma cell lines. While cytolytic activity was observed in melanoma cell lines, no activation of the T cell clones could be detected in the presence of ALL cell lines, which was postulated to be most probably linked to the lower expression of PRAME in the latter [69]. Moreover, an association between PRAME expression levels and multi-epitope PRAME-specific CD8+ T cell responses has been reported in leukemia [77]. In the same study, it was shown that leukemia patients naturally have higher frequencies of PRAME-specific precursor T cells compared to healthy controls. It remains to be determined whether this is linked to the ability of pre-existing PRAME-specific T cells to target leukemic progenitor cells in addition to leukemic blasts [70]. Together, these findings suggest that there is possibly a recognition threshold for PRAME expression in order to induce cytotoxic T cell responses. This is where epigenetic modulators, such as DMAs and HDACis, come into play to upregulate PRAME expression. However, caution is warranted as the impact of re-expression of
a tumor-associated antigen in normal tissues remains unknown and epigenetic agents may alter immune cell function. Moreover, the upregulation of PRAME in low-expressing cancer cell clones will likely increase their metastatic potential via PRAME-mediated EMT; hence, the optimal dosage and therapeutic window of opportunity will need to be carefully considered when administering combination treatment of demethylation drugs and PRAME-specific immunotherapy.

Although increasing target expression represents one approach to improve the efficacy of targeted immunotherapy, positive tumor cells can still evade the anti-tumor immune response through several mechanisms. For example, dedifferentiated liposarcoma and leiomyosarcoma tumors with positive PRAME expression have been found to express reduced levels of antigen presentation molecules, such as HLA-B, HLA-C, beta-2 microglobulin (B2M), latent membrane proteins 2 and 7 (LMP2, LMP7), and transporter associated with antigen processing 2 (TAP2) [30]. This suggests that PRAME-positive tumors can elicit an immune response and therefore downregulate the antigen presentation machinery in order to avoid immune recognition. Hence, it might be possible to improve the efficacy of PRAME-targeted immunotherapy using agents that can increase MHC class I expression, such as DNA demethylating drugs, HDAC inhibitors, inducers of the tumor suppressor Fhit, and MEK inhibitors [78]. Interestingly, combinatorial cellular immunotherapy using PRAME-specific T cells with NK cell-based therapy could also possibly increase the therapeutic response. Co-culture of activated NK cells with neuroblastoma cell lines demonstrated that the tumor cells could upregulate the expression of MHC class I molecules through NK contact-dependent production of IFN-γ, resulting in increased PRAME-specific T cell killing of the tumor cells [79]. On the other hand, PRAME expression has been observed in association with reduced PD-L1 expression in dedifferentiated liposarcoma, which appears to be contraindicative of the notion that PRAME could facilitate immune evasion. The molecular mechanisms underlying this association are currently unknown; however, numerous studies have reported on the regulation of the tumor expression of PD-L1. For example, PD-L1 expression can be induced by c-Myc [80], so it remains to be determined whether an increase in PRAME expression, alone or in conjunction with changes in c-Myc expression, could negatively regulate PD-L1 surface expression. Moreover, a recent study demonstrated that PD-L1 stability is regulated in a cell-cycle-dependent manner via a Cullin E3 ligase [81], which has been found to co-localize with PRAME in the Golgi network as previously mentioned. Nevertheless, whether PRAME is directly linked to PD-L1 and/or PD-1 expression, and hence anti-tumor immunity and response to the PD-L1/PD-1 blockade, remains unknown and warrants further investigation. Interestingly, PD-L1 expression is commonly not observed on blast cells from patients with AML, providing a potential mechanistic link for a PRAME-associated favorable outcome in these patients. Furthermore, PRAME-expressing tumors, such as advanced soft-tissue sarcomas, including dedifferentiated liposarcomas, exhibit a low response rate of 18% to anti PD-1 treatment (NCT02301039) [30,82]. Besides reduced PD-L1 tumor expression, many additional factors could contribute to resistance to anti-PD-1 therapy, including low numbers of exhausted high-avidity T cells, upregulation of other immune checkpoint molecules and receptors such as VISTA and TIM-3, loss of IFN-γ response elements, and macrophage-sequestration of the therapeutic anti-PD1 antibody [83]. Indeed, it is possible that pre-existing PRAME-specific T cells are at least partially anergic, since vaccination of patients with PRAME-specific T cells at baseline did not induce T cell expansion to the same extent as vaccination of patients without pre-existing PRAME specific T cells [64]. Hence, the question arises as to whether the efficacy of PRAME adoptive T cell therapy could be enhanced by treatment with immune checkpoint inhibitors. To the best of our knowledge, there are currently no published reports or active/recruiting clinical trials investigating this therapeutic approach.

Interestingly, antibody-based targeting of PRAME has emerged as a novel approach, which could offer a new avenue to induce potent anti-tumor responses. PRAME was, until recently, not considered a candidate target for antibody therapy, as monoclonal antibodies exclusively bind to the cell surface and extracellular antigens, while cancer testis antigens are intracellular antigens. However, a research group from the Memorial Sloan Kettering Cancer Center developed a TCR mimic human antibody
that can recognize the PRA300–309 peptide in a complex with HLA-A2 [75]. The afucosylated Fc form of the Pr20 antibody was able to bind to HLA-A2+ PRAME+ leukemia and lymphoma cells in vitro and to induce antibody dependent cellular cytotoxicity (ADCC) in a dose-dependent manner. The authors reported that the TCR mimic required tumor cells to induce expression of the immunoproteasome in order to correctly process the PRA300–309 peptide, as demonstrated by the lack of Pr20 binding and ADCC in several HLA-A2+ PRAME+ melanoma cell lines. In a follow-up study, the authors demonstrated that antibody-dependent phagocytosis of PRAME-expressing cancer cells could be enhanced using a combinatorial treatment of PRAME TCRm mAbs with CD47 blockade, thereby releasing the inhibition of macrophage phagocytosis [76]. Thus, monoclonal antibodies targeting PRAME could be an additional viable treatment option for hematological as well as solid cancers in combination with IFN-γ mediated upregulation of the immunoproteasome, which renders PRAME a preferable CTA to target. This also opens up opportunities to enhance the anti-tumor response using antibody–drug conjugates or radio-immunoconjugates.

Although PRAME is widely believed to be an intracellular antigen, one study detected a membrane-bound form of PRAME in chronic lymphocytic leukemia and mantle cell lymphoma [84]. This result sparked the development of the polyclonal antibody Membrane associated PRAME Antibody 1 (MPA1) against the predicted extracellular PRA310-331 peptide [74]. The authors demonstrated specific binding of MPA1 to PRAME+ liquid and solid cancer cell lines, with increased binding upon demethylation treatment. However, the specificity of the MPA1 antibody was not evaluated in engineered cell line models to allow the evaluation of antibody binding in a single cell line before and after the manipulation of PRAME expression (knockout or overexpression). As a proof-of-principle model for in vivo targeting of PRAME using antibodies, the authors reported highly specific tumor uptake of radiolabeled MPA1 in xenograft mice. In order to limit cross-reactivity, they are currently developing a monoclonal antibody against the PRA300–309 peptide. The identification of a membrane-bound form of PRAME further opens up the possibility to target membrane-bound PRAME-expressing tumor cells with CART cell therapy, expanding the spectrum of tools for PRAME-targeted immunotherapy in comparison with the available approaches to target other CTAs.

6. Conclusions

Given the widespread re-expression of PRAME among malignancies and the novel developments in the immunotherapy field, we believe that there is great potential to target PRAME using a variety of immune-based interventions, either as single modality or as a combinatorial treatment. We discussed some of the major challenges for PRAME-based immunotherapy that need to be addressed, including the intra- and inter-tumor heterogeneous expression of PRAME and the potential role of PRAME in the upregulation of immune evasion mechanisms. Furthermore, we described the current countermeasures and innovative technologies that are being exploited to improve the potency of the PRAME-specific anti-tumor response.

Among all cancer testis antigens, PRAME is in a unique position as it is not only widely expressed in various cancers but also elicits specific cellular immune responses against numerous neoplastic cells as well as against leukemia progenitor cells, plays a role in the innate immune response and possibly also the adaptive anti-tumor immune response, could enhance the ATRA treatment response as a combinational therapy, and could be targeted using a wider range of approaches including antibody- and CAR-based therapies.

**Author Contributions:** Conceptualization, J.D.; Literature review, G.A.-K.; Writing—Original Draft Preparation, G.A.-K.; Writing—Review & Editing, J.D. and G.A.-K.; Visualization, J.D. All authors have read and approved the submitted version of the manuscript.

**Funding:** This work was supported by the Qatar Biomedical Research Institute under grant #VR80 and the Qatar National Research Fund under grant #QRLP10-G-1803024. The publication of this article was funded in part by the Qatar National Library.

**Conflicts of Interest:** The authors declare no conflict of interest.
References
1. Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M.; et al. Adjuvant trastuzumab in HER2-positive breast cancer. *N. Engl. J. Med.* 2011, 365, 1273–1283. [CrossRef] [PubMed]
2. Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, P.; et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N. Engl. J. Med.* 2002, 346, 235–242. [CrossRef] [PubMed]
3. Ly, Z.-C.; Ning, J.-Y.; Chen, H.-B. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis from 12 randomized controlled trials. *Tumor Biol.* 2014, 35, 11741–11750. [CrossRef] [PubMed]
4. Zhang, H.; Chen, J. Current status and future directions of cancer immunotherapy. *J. Cancer* 2018, 9, 1773–1781. [CrossRef] [PubMed]
5. Hinrichs, C.S.; Rosenberg, S.A. Exploiting the curative potential of adoptive T-cell therapy for cancer. *Immunol. Rev.* 2014, 257, 56–71. [CrossRef] [PubMed]
6. Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Phan, G.Q.; Restifo, N.P.; Robbins, P.F.; Wunderlich, J.R.; et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* 2011, 17, 4550–4557. [CrossRef]
7. Hay, K.A.; Turtle, C.J. Chimeric Antigen Receptor (CAR) T cells: Lessons Learned from Targeting of CD19 in B cell malignancies. *Drugs* 2017, 77, 237–245. [CrossRef]
8. Robbins, P.F.; Morgan, R.A.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.; Dudley, M.E.; Wunderlich, J.R.; Nahvi, A.V.; Helman, L.J.; Mackall, C.L.; et al. Tumor Regression in Patients with Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. *J. Clin. Oncol.* 2011, 29, 917–924. [CrossRef]
9. Thomas, R.; Al-Khadairi, G.; Roelands, J.; Hendrickx, W.; Dermietz, S.; Bedognetti, D.; Decock, J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. *Front. Immunol.* 2018, 9, 947. [CrossRef]
10. Fratta, E.; Coral, S.; Covre, A.; Parisi, G.; Colizzi, F.; Danielli, R.; Marie Nicolay, H.J.; Sigalotti, L.; Maio, M. The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. *Mol. Oncol.* 2011, 5, 164–182. [CrossRef]
11. Simpson, A.J.G.; Caballero, O.L.; Jungbluth, A.; Chen, Y.-T.; Old, L.J. Cancer/testis antigens, gametogenesis and cancer. *Nat. Rev. Cancer* 2005, 5, 615–625. [CrossRef] [PubMed]
12. Yao, J.; Caballero, O.L.; Yung, W.K.A.; Weinstein, J.N.; Riggins, G.J.; Strausberg, R.L.; Zhao, Q. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. *Cancer Immunol. Res.* 2014, 2, 371–379. [CrossRef] [PubMed]
13. Zajac, P.; Schultz-Thater, E.; Tornillo, L.; Sadowski, C.; Trella, E.; Mengus, C.; Iezzi, G.; Spagnoli, G.C. MAGE-A Antigens and Cancer Immunotherapy. *Front. Med.* 2017, 4, 18. [CrossRef] [PubMed]
14. Ikeda, H.; Léthé, B.; Lehmann, F.; van Baren, N.; Baurain, J.F.; de Smet, C.; Chambost, H.; Vitale, M.; Moretta, A.; Boon, T.; et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. *Immunity* 1997, 6, 199–208. [CrossRef]
15. Almeida, L.G.; de Oliveira, A.R.; Silva, M.C.C.; Mundstein, A.S.; Cohen, T.; Chen, Y.-T.; Chua, R.; Gurung, S.; Gnjatic, S.; et al. CTdatabase: A knowledge-base of high-throughput and curated data on cancer-testis antigens. *Nucleic Acids Res.* 2009, 37, D816–D819. [CrossRef] [PubMed]
16. Lee, Y.-K.; Park, U.-H.; Kim, E.-J.; Hwang, J.-T.; Jeong, J.-C.; Um, S.-J. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. *Cancer Lett.* 2017, 403, 144–151. [CrossRef] [PubMed]
17. Sakurai, E.; Maesawa, C.; Shibazaki, M.; Yasuhira, S.; Oikawa, H.; Sato, M.; Tsunoda, K.; Ishikawa, Y.; Watanabe, A.; Takahashi, K.; et al. Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. *Int. J. Oncol.* 2011, 39, 665–672. [PubMed]
18. Haqq, C.; Nosrati, M.; Sudilovsky, D.; Crothers, J.; Khodakakhsh, D.; Pulliam, B.L.; Federman, S.; Miller, J.R.; Allen, R.E.; Singer, M.I.; et al. The gene expression signatures of melanoma progression. *Proc. Natl. Acad. Sci. USA* 2005, 102, 6092–6097. [CrossRef]
19. Epping, M.T.; Bernards, R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. *Cancer Res.* 2006, 66, 10639–10642. [CrossRef]
20. Neumann, E.; Engelsberg, A.; Decker, J.; Störl, S.; Jaeger, E.; Huber, C.; Seliger, B. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies? *Cancer Res.* 1998, 58, 4090–4095. [CrossRef] [PubMed]

21. Bankovic, J.; Stojisic, J.; Jovanovic, D.; Andjelkovic, T.; Milinkovic, V.; Ruzdijic, S.; Tanic, N. Identification of genes associated with non-small-cell lung cancer promotion and progression. *Lung Cancer* 2010, 67, 151–159. [CrossRef] [PubMed]

22. Oberthuer, A.; Hero, B.; Spitz, R.; Berthold, F.; Fischer, M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. *Clin. Cancer Res.* 2004, 10, 4307–4313. [CrossRef] [PubMed]

23. Doolan, P.; Clynes, M.; Kennedy, S.; Mehta, J.P.; Crown, J.; O’Driscoll, L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. *Breast Cancer Res. Treat.* 2008, 109, 359–365. [CrossRef] [PubMed]

24. Epping, M.T.; Hart, A.A.M.; Glas, A.M.; Krijgsman, O.; Bernards, R. PRAME expression and clinical outcome of breast cancer. *Br. J. Cancer* 2008, 99, 398–403. [CrossRef] [PubMed]

25. Wadelin, F.; Fulton, J.; McEwan, P.A.; Spriggs, K.A.; Emsley, J.; Heery, D.M. Leucine-rich-repeat protein PRAME: Expression, potential functions and clinical implications for leukaemia. *Mol. Cancer* 2010, 9, 226. [CrossRef] [PubMed]

26. Pellat-Deceunynck, C.; Mellerin, M.P.; Labarriere, N.; Jego, G.; Moreau-Aubry, A.; Harousseau, J.L.; Jotereau, F.; Bataille, R. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. *Eur. J. Immunol.* 2000, 30, 803–809. [CrossRef]

27. Greiner, J.; Ringhoffer, M.; Taniguchi, M.; Li, L.; Schmitt, A.; Shiku, H.; Döhner, H.; Schmitt, M. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. *Int. J. Cancer* 2004, 108, 704–711. [CrossRef]

28. Ding, K.; Wang, X.-M.; Fu, R.; Ruan, E.-B.; Liu, H.; Shao, Z.-H. PRAME Gene Expression in Acute Leukemia and Its Clinical Significance. *Clin. Sarcoma Res.* 2017, 7, 11. [CrossRef]

29. Luk, S.J.; van der Steen, D.M.; Hagedoorn, R.S.; Jordanova, E.S.; Schilham, M.W.; Bovée, J.V.; Cleven, A.H.; Falkenburg, J.F.; Szuhai, K.; Heemskerk, M.H. PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. *Oncoimmunology* 2018, 7, e1507600. [CrossRef] [PubMed]

30. Sigalotti, L.; Fratta, E.; Coral, S.; Tanzarella, S.; Danielli, R.; Colizzi, F.; Fonsatti, E.; Traversari, C.; Altomonte, M.; Maio, M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. *Cancer Res.* 2004, 64, 9167–9171. [CrossRef]

35. Woloszynska-Read, A.; Mhawech-Fauceglia, P.; Yu, J.; Odunsi, K.; Karpf, A.R. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. *Clin. Cancer Res.* 2008, 14, 3283–3290. [CrossRef] [PubMed]

36. Schenk, T.; Stengel, S.; Goellner, S.; Steinbach, D.; Saluz, H.P. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. *Genes. Chromosomes Cancer* 2007, 46, 796–804. [CrossRef] [PubMed]
37. Ortmann, C.A.; Eisele, L.; Nückel, H.; Klein-Hitpass, L.; Führer, A.; Dühren, U.; Zeschning, M. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. *Ann. Hematol.* 2008, 87, 809. [CrossRef]

38. Luetkens, T.; Schafhausen, P.; Uhlich, F.; Stasche, T.; Akbulak, R.; Bartels, B.M.; Hildebrandt, Y.; Gontarewicz, A.; Kobold, S.; Meyer, S.; et al. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. *Leuk. Res.* 2010, 34, 1647–1655. [CrossRef]

39. Tan, P.; Zou, C.; Yong, B.; Han, J.; Zhang, L.; Su, Q.; Yin, J.; Wang, J.; Huang, G.; Peng, T.; et al. Expression and prognostic relevance of PRAME in primary osteosarcoma. *Biochem. Biophys. Res. Commun.* 2012, 419, 801–808. [CrossRef]

40. Iura, K.; Maekawa, A.; Yamada, Y.; Yamamoto, H.; Iwamoto, Y.; Oda, Y. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. *J. Pathol. Clin. Res.* 2015, 1, 144–159. [CrossRef]

41. Iura, K.; Maekawa, A.; Kohashi, K.; Ishii, T.; Bekki, H.; Otsuka, H.; Yamada, Y.; Yamamoto, H.; Harimaya, K.; Iwamoto, Y.; et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. *Hum. Pathol.* 2017, 61, 130–139. [CrossRef] [PubMed]

42. Szczepanski, M.J.; DeLeo, A.B.; Łuczak, M.; Molinska-Glura, M.; Misiak, J.; Szarzynska, B.; Dworacki, G.; Zagor, M.; Rozwadowska, N.; Kurpisz, M.; et al. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. *Oral Oncol.* 2013, 49, 144–151. [CrossRef] [PubMed]

43. Orlando, D.; Miele, E.; De Angelis, B.; Guercio, M.; Bo, A.; et al. Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma. *Cancer Res.* 2018, 78, 3337–3349. [CrossRef] [PubMed]

44. Santamaría, C.; Chillón, M.C.; García-Sanz, R.; Balanzategui, A.; Sarasquete, M.E.; Alcoceba, M.; Ramos, F.; Bernal, T.; Queizán, J.A.; Peñarrubia, M.J.; et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. *Haematologica* 2008, 93, 1797–1805. [CrossRef] [PubMed]

45. Steinbach, D.; Hermann, J.; Viehmann, S.; Zintl, F.; Gruhn, B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. *Cancer Genet.* Cyto. 2002, 133, 118–123. [CrossRef]

46. Abdelmalak, C.A.; Yahya, R.S.; Elghannam, D.M.; El-Khadragy, A.E.; Abd El Messih, H.M. PRAME gene expression in childhood acute lymphoblastic leukemia: Impact on prognosis. *Clin. Lab.* 2014, 60, 55–61. [CrossRef] [PubMed]

47. Zhang, Y.-H.; Lu, A.-D.; Yang, L.; Li, L.-D.; Chen, W.-M.; Long, L.-Y.; Zhang, L.-P.; Qin, Y.-Z. PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy. *Leuk. Res.* 2017, 52, 43–49. [CrossRef]

48. Greiner, J.; Schmitt, M.; Li, L.; Giannopoulos, K.; Bosch, K.; Schmitt, A.; Dohner, K.; Schlenk, R.F.; Pollack, J.R.; Dohner, H.; et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. *Blood* 2006, 108, 4109–4117. [CrossRef] [PubMed]

49. Matsushita, M.; Ikeda, H.; Kizaki, M.; Okamoto, S.; Ogasawara, M.; Ikeda, Y.; Kawakami, Y. Quantitative expression of the cancer-testis antigen PRAME in primary osteosarcoma. *Biochem. Biophys. Res. Commun.* 2012, 419, 801–808. [CrossRef]
Cancers 2019, 11, 984

54. Costessi, A.; Mahour, N.; Sharma, V.; Stunnenberg, R.; Stoel, M.A.; Tijchon, E.; Conaway, J.W.; Conaway, R.C.; Stunnenberg, H.G. The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME. PLoS ONE 2012, 7, e42822. [CrossRef] [PubMed]

55. Costessi, A.; Mahour, N.; Tijchon, E.; Stunnenberg, R.; Stoel, M.A.; Jansen, P.W.; Sela, D.; Martin-Brown, S.; Washburn, M.P.; Flores, L.; et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J. 2011, 30, 3786–3798. [CrossRef]

56. Downey, M.; Houlsworth, R.; Maringlele, L.; Rollie, A.; Brehme, M.; Galicia, S.; Guillard, S.; Partington, M.; Zubko, M.K.; Krogan, N.J.; et al. A genome-wide screen identifies the evolutionarily conserved KEOPS complex as a telomere regulator. Cell 2006, 124, 1155–1168. [CrossRef]

57. Roman-Gomez, J.; Jimenez-Velasco, A.; Agirre, X.; Castillejo, J.A.; Navarro, G.; Jose-Eneriz, E.S.; Garate, L.; Downey, M.; Houlsworth, R.; Maringlele, L.; Rollie, A.; Brehme, M.; Galicia, S.; Guillard, S.; Partington, M.; Zubko, M.K.; Krogan, N.J.; et al. A genome-wide screen identifies the evolutionarily conserved KEOPS complex as a telomere regulator. Cell 2006, 124, 1155–1168. [CrossRef]

58. Gerber, J.M.; Qin, L.; Kowalski, J.; Smith, B.D.; Griffin, C.A.; Vala, M.S.; Collector, M.I.; Perkins, B.; Zahurak, M.; Matsui, W.; et al. Characterization of chronic myeloid leukemia stem cells. Am. J. Hematol. 2011, 86, 31–37. [CrossRef]

59. Al-Khadairi, G.; Naik, A.; Thomas, R.; Al-Sulaiti, B.; Rizly, S.; Decock, J. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J. Transl. Med. 2019, 17, 9. [CrossRef]

60. Wadelin, F.R.; Fulton, J.; Collins, H.M.; Tertipis, N.; Bottley, A.; Spriggs, K.A.; Falcone, F.H.; Heery, D.M. PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs. PLoS ONE 2013, 8, e58052. [CrossRef]

61. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883–899. [CrossRef] [PubMed]

62. Williams, J.M.; Chen, G.C.; Zhu, L.; Rest, R.F. Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: Intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol. Microbiol. 1998, 27, 171–186. [CrossRef] [PubMed]

63. Pujo, J.-L.; De Pas, T.; Rittmeyer, A.; Vallières, E.; Kubisa, B.; Levchenco, E.; Wiesemann, S.; Masters, G.A.; Shen, R.; Tjulandin, S.A.; et al. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. J. Thorac. Oncol. 2016, 11, 2208–2217. [CrossRef] [PubMed]

64. Weber, J.S.; Vogelzang, N.J.; Ernstoff, M.S.; Goodman, O.B.; Cranmer, L.D.; Marshall, J.L.; Miles, S.; Rosario, D.; Diamond, D.C.; Qiu, Z.; et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J. Immunother. 2011, 34, 556–567. [CrossRef] [PubMed]

65. Gérard, C.; Baudson, N.; Ory, T.; Segal, L.; Louahed, J. A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined with the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors. J. Immunother. 2015, 38, 311–320. [CrossRef] [PubMed]

66. Gutzmer, R.; Rivoltini, L.; Levchenco, E.; Testori, A.; Utikal, J.; Ascierto, P.A.; Demidov, L.; Grob, J.J.; Ridolfi, R.; Schadendorf, D.; et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: Results of a phase I dose escalation study. ESMO Open 2016, 1, e000068. [CrossRef] [PubMed]

67. Vansteenwegen, J.F.; Cho, B.C.; Vanakesa, T.; De Pas, T.; Zielinski, M.; Kim, M.S.; Jassem, J.; Yoshimura, M.; Dahabreh, J.; Nakayama, H.; et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016, 17, 822–835. [CrossRef]

68. Kessler, J.H.; Beekman, N.J.; Bres-Vloemans, S.A.; Verdijk, P.; van Veen, P.A.; Kloosterman-Joosten, A.M.; Vissers, D.C.; ten Bosch, G.J.; Kester, M.G.; Sijs, A.; et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 2001, 193, 73–88. [CrossRef] [PubMed]

69. Griffioen, M.; Kessler, J.H.; Borghi, M.; van Soest, R.A.; van der Minne, C.E.; Nouta, J.; van der Burg, S.H.; Medema, J.P.; Schrier, P.I.; Falkenburg, J.H.F.; et al. Detection and functional analysis of CD8+ T cells specific for PRAME: A target for T-cell therapy. Clin. Cancer Res. 2006, 12, 3130–3136. [CrossRef]
70. Quintarelli, C.; Dotti, G.; Hasan, S.T.; De Angelis, B.; Hoyos, V.; Errichiello, S.; Mims, M.; Luciano, L.; Shafer, J.; Leen, A.M.; et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. *Blood* 2011, 117, 3353–3362. [CrossRef]

71. Amir, A.L.; van der Steen, D.M.; van Loenen, M.M.; Hagedoorn, R.S.; de Boer, R.; Kester, M.D.G.; de Ru, A.H.; Lugthart, G.J.; van Kooten, C.; Hiemstra, P.S.; et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. *Clin. Cancer Res.* 2011, 17, 5615–5625. [CrossRef] [PubMed]

72. Yan, M.; Himoudi, N.; Basu, B.P.; Wallace, R.; Poon, E.; Adams, S.; Hasan, F.; Xue, S.-A.; Wilson, N.; Dalgleish, A.; et al. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2’-Deoxycytidine. *Cancer Immunol. Immunother.* 2011, 60, 1243–1255. [CrossRef] [PubMed]

73. Yao, Y.; Zhou, J.; Wang, L.; Gao, X.; Ning, Q.; Jiang, M.; Wang, J.; Wang, L.; Yu, L. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. *PLoS ONE* 2013, 8, e70522. [CrossRef]

74. Pankov, D.; Sjöström, L.; Kalindini, T.; Lee, S.-G.; Sjöström, K.; Gardner, R.; McDevitt, M.R.; O’Reilly, R.; Thorek, D.L.J.; Larson, S.M.; et al. In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). *Oncotarget* 2017, 8, 65917–65931. [CrossRef] [PubMed]

75. Chang, A.Y.; Dao, T.; Gejman, R.S.; Jarvis, C.A.; Scott, A.; Dubrovsky, L.; Mathias, M.D.; Korontsvit, T.; Zakhaleva, V.; Curcio, M.; et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. *J. Clin. Investig.* 2017, 127, 2705–2718. [CrossRef] [PubMed]

76. Mathias, M.D.; Sockolosky, J.T.; Chang, A.Y.; Tan, K.S.; Liu, C.; Garcia, K.C.; Scheinberg, D.A. CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. *Leukemia* 2017, 31, 2254–2257. [CrossRef] [PubMed]

77. Rezvani, K.; Yong, A.S.M.; Mielke, S.; Savani, B.N.; Musse, L.; Superata, J.; Jafarpour, B.; Boss, C.; Barrett, A.J. Leukemia-associated antigen-specific T-cell responses following combined PRI and WT1 peptide vaccination in patients with myeloid malignancies. *Blood* 2008, 111, 236–242. [CrossRef] [PubMed]

78. Garrido, F.; Aptsiauri, N.; Doorduijn, E.M.; Garcia Lora, A.M.; van Hall, T. The urgent need to recover MHC class I in cancers for effective immunotherapy. *Curr. Opin. Immunol.* 2016, 39, 44–51. [CrossRef]

79. Spel, L.; Boelens, J.J.; van der Steen, D.M.; Blokland, N.J.G.; van Noesel, M.M.; Molenaar, J.J.; Heemskerk, M.H.M.; Boes, M.; Nierkens, S. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. *Oncotarget* 2015, 6, 35770–35781. [CrossRef]

80. Casey, S.C.; Tong, L.; Li, Y.; Do, R.; Walz, S.; Fitzgerald, K.N.; Gouw, A.M.; Baylot, V.; Gürtgemann, I.; Eilers, M.; et al. MYC regulates the antitumor immune response through CD47 and PD-L1. *Science* 2016, 352, 227–231. [CrossRef] [PubMed]

81. Zhang, J.; Bu, X.; Wang, H.; Zhu, Y.; Geng, Y.; Nihira, N.T.; Tan, Y.; Ci, Y.; Wu, F.; Dai, X.; et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. *Nature* 2018, 553, 91–95. [CrossRef] [PubMed]

82. Tawbi, H.A.; Burgess, M.; Bolejock, V.; Van Tine, B.A.; Schuetze, S.M.; Hu, J.; D’Angelo, S.; Attia, S.; Riedel, R.F.; Priebat, D.A.; et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol.* 2017, 18, 1493–1501. [CrossRef] [PubMed]

83. Seidel, J.A.; Otsuka, A.; Kabashima, K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. *Front. Oncol.* 2018, 8, 86. [CrossRef] [PubMed]

84. Proto-Siqueira, R.; Figueiredo-Pontes, L.L.; Panepucci, R.A.; Garcia, A.B.; Rizzatti, E.G.; Nascimento, E.M.; Ishikawa, H.C.F.; Larson, R.E.; Falcão, R.P.; Simpson, A.J.; et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. *Leuk. Res.* 2006, 30, 1333–1339. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).